Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CDIO 
Cardio Diagnostics Holdings Inc (CDIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CDIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $60
1 Year Target Price $60
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 3.47% | Avg. Invested days 64 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.68M USD | Price to earnings Ratio - | 1Y Target Price 60 |
Price to earnings Ratio - | 1Y Target Price 60 | ||
Volume (30-day avg) 1 | Beta 2.91 | 52 Weeks Range 3.22 - 53.10 | Updated Date 08/29/2025 |
52 Weeks Range 3.22 - 53.10 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.75 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.22 | Actual -0.97 |
Profitability
Profit Margin - | Operating Margin (TTM) -22457.51% |
Management Effectiveness
Return on Assets (TTM) -54.15% | Return on Equity (TTM) -97.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -737809 | Price to Sales(TTM) 342.56 |
Enterprise Value -737809 | Price to Sales(TTM) 342.56 | ||
Enterprise Value to Revenue 158.51 | Enterprise Value to EBITDA -22.48 | Shares Outstanding 1763130 | Shares Floating 1630295 |
Shares Outstanding 1763130 | Shares Floating 1630295 | ||
Percent Insiders 7.16 | Percent Institutions 5.02 |
Upturn AI SWOT
Cardio Diagnostics Holdings Inc
Company Overview
History and Background
Cardio Diagnostics Holdings Inc. is focused on cardiovascular disease detection through artificial intelligence (AI)-driven electrocardiogram (ECG) solutions. The company provides integrated genetic-clinical risk scores designed to improve the early detection and prevention of cardiovascular disease.
Core Business Areas
- Integrated Genetic-Clinical Risk Scores: Offers integrated genetic-clinical risk scores for early detection and prevention of cardiovascular disease.
- AI-Driven ECG Solutions: Develops and utilizes artificial intelligence to enhance the analysis and interpretation of electrocardiogram data.
Leadership and Structure
Details on the specific leadership team and organizational structure of Cardio Diagnostics Holdings Inc. would require further research into the company's filings and website. Generally, such structures include a CEO, CFO, CTO, and board of directors.
Top Products and Market Share
Key Offerings
- Epi+Gen CHD: A blood based genetic test providing a risk score for coronary heart disease. Market share is difficult to ascertain for this early stage company. Competitors include companies offering similar genetic tests or traditional cardiovascular risk assessment methods.
- PrecisionCHD: Clinical test that uses patient's clinical data to identify and predict a patient's heart health. Market share is difficult to ascertain for this early stage company. Competitors include companies offering similar tests.
Market Dynamics
Industry Overview
The cardiovascular diagnostics industry is growing, driven by increasing prevalence of heart disease, advancements in diagnostic technologies, and a focus on preventative care.
Positioning
Cardio Diagnostics Holdings Inc. aims to differentiate itself through AI-driven solutions and integrated genetic-clinical risk scores, targeting early detection and personalized care.
Total Addressable Market (TAM)
The cardiovascular disease diagnostics market is estimated in the billions of dollars globally. Cardio Diagnostics Inc. aims to capture a share of this by focusing on more accurate and earlier disease detection.
Upturn SWOT Analysis
Strengths
- AI-driven technology
- Integrated genetic-clinical risk scores
- Focus on early detection
- Proprietary technology
Weaknesses
- Limited market share as an early-stage company
- Reliance on funding
- Limited brand recognition
- Regulatory hurdles for new diagnostic tests
Opportunities
- Partnerships with healthcare providers
- Expansion into new markets
- Development of new diagnostic tools
- Increasing awareness of preventative care
Threats
- Competition from established diagnostic companies
- Changing healthcare regulations
- Technological advancements by competitors
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- MYGN
- ILMN
- HOLX
- NVTA
Competitive Landscape
Cardio Diagnostics Holdings Inc. competes with larger, more established diagnostic companies. Its advantage lies in its AI-driven approach, but it faces challenges in scaling and competing for market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data requires access to past financial reports.
Future Projections: Future growth projections are based on analyst estimates, which can vary. These are often tied to clinical trial results and commercialization success.
Recent Initiatives: Information on recent initiatives would be found in company press releases and investor presentations.
Summary
Cardio Diagnostics Holdings Inc. is an early-stage company with innovative AI-driven diagnostic technology targeting cardiovascular disease. While its technology holds promise, the company faces challenges in scaling, gaining market share, and securing funding. Success depends on partnerships, regulatory approvals, and demonstrating the clinical and economic value of its products. Investors should monitor clinical trial results and market adoption rates closely.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
- Industry Reports
Disclaimers:
This analysis is based on available information and is not financial advice. Market share data is estimated due to the limited public information available for Cardio Diagnostics Holdings Inc.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cardio Diagnostics Holdings Inc
Exchange NASDAQ | Headquaters Chicago, IL, United States | ||
IPO Launch date 2022-01-14 | Co-Founder, CEO & Director Dr. Meeshanthini V. Dogan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://cdio.ai |
Full time employees 13 | Website https://cdio.ai | ||
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, including concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.